A lot can change in a month, especially with biotech stocks. Back in mid-March, one of our stock’s shares were in the midteens. Then, a European regulatory committee recommended approval for our company’s lead drug, vintafolide, to treat ovarian cancer in patients that have become resistant to platinum-based therapies. Shares nearly doubled on the news, and we recommended selling half of our shares to secure a 266% return and hedge against future risks.
↧